{"disease":{"id":"oestrogen-receptor-positive-breast-cancer","name":"oestrogen receptor positive breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01743560","title":"An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06613516","title":"Effect of Capivasertib on ctDNA in ER Positive Breast Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Imperial College London","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}